<DOC>
	<DOCNO>NCT01174446</DOCNO>
	<brief_summary>The purpose pivotal Phase 1/3 study determine pharmacokinetic ( PK ) parameter , hemostatic efficacy , safety BAX 326 , recombinant factor IX , previously treat patient ( PTPs ) severe moderately severe hemophilia B .</brief_summary>
	<brief_title>Pivotal Study ( Pharmacokinetics , Efficacy , Safety ) BAX 326 ( rFIX ) Hemophilia B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Main Participant 12 65 year old time screen Participant and/or legal representative has/have provide sign informed consent Participant severe ( factor IX ( FIX ) level &lt; 1 % ) moderately severe ( FIX level 12 % ) hemophilia B ( base one stage activate partial thromboplastin time ( aPTT ) assay ) , test screening central laboratory Participant previously treat plasmaderived recombinant FIX concentrate ( ) minimum 150 exposure day ( EDs ) ( base participant 's medical record ) ; verifiable , documented history unavailable , participant enrol s/he 100150 EDs FIX product fully document participate Study 050901 least 50 EDs Immunine prior enrollment ( valid US Japan ) . Participant evidence history FIX inhibitor If participant receive prophylactic treatment , participant willing receive prophylactic treatment period 6 month . If participant receive ondemand treatment , participant ≥12 document bleed episode require treatment within 12 month prior enrollment willing receive ondemand treatment duration study . Main The participant history FIX inhibitor titer ≥0.6 Bethesda Units ( BU ) ( determine Nijmegen modification Bethesda assay assay employ respective local laboratory ) time prior screen The participant detectable FIX inhibitor screening , titer ≥0.6 BU determine Nijmegen modification Bethesda assay central laboratory The participant 's weight &lt; 35 kg &gt; 120 kg The participant history allergic reaction , eg , anaphylaxis , follow exposure FIX concentrate ( ) The participant know hypersensitivity hamster proteins recombinant furin ( rFurin ) The participant ongoing recent evidence thrombotic disease , fibrinolysis disseminate intravascular coagulation ( DIC )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>